Table 2.
Anal HPV type prevalence.
| N=182 | Positive |
|---|---|
| HPV 6 | 36 (20%) |
| HPV 11 | 41 (23%) |
| HPV 16 | 66 (36%) |
| HPV 18 | 9 (5%) |
| HPV 31 | 14 (8%) |
| HPV 33 | 8 (4%) |
| HPV 35 | 5 (3%) |
| HPV 39 | 37 (20%) |
| HPV 40 | 18 (l0%) |
| HPV 42 | 30 (l6%) |
| HPV 43 | 8 (4%) |
| HPV44/55a | 36 (20%) |
| HPV 45 | 16 (9%) |
| HPV 51 | 41 (23%) |
| HPV 52 | 34 (l9%) |
| HPV 53 | 18 (l0%) |
| HPV 56 | 22 (l2%) |
| HPV 58 | 20 (ll%) |
| HPV 59 | 29 (l6%) |
| HPV 66 | 15 (8%) |
| HPV 68 | 32 (l8%) |
| HPV 70 | 40 (22%) |
| HPV 73 | 5 (3%) |
| HPV 82 | 11 (6%) |
| Any positive HPV subtype | 169 (93%) |
| ≥one 9vHPV vaccine type | 132 (73%) |
| (6,11,16,18,31,33,45,52,58) | |
HPV: human papillomavirus; 9vHPV: nine-valent HPV vaccine.
a
One South African participant did not have HPV 44/55 results available.